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ΠΡΟΛΟΓΟΣ 
Η παρούσα Διπλωματική Εργασία, εκπονήθηκε στα πλαίσια του Μεταπτυχιακού 
Προγράμματος «Μεθοδολογία Βιοϊατρικής Έρευνας, Βιοστατιστική και Κλινική 
Βιοπληροφορική» του Τμήματος  Ιατρικής του Πανεπιστημίου Θεσσαλίας.  
Το αντικείμενο αφορά σε πρωτόκολλο κλινικής μελέτης σχετικά με την 
αποτελεσματικότητα και την ανεκτικότητα της Ιντερφερόνης β-1a σε ασθενείς με 
υποτροπιάζουσα-διαλείπουσα πολλαπλή σκλήρυνση. Πρόκειται για μια προοπτική μελέτη 
παρατήρησης που περιλαμβάνει 250 ασθενείς με υποτροπιάζουσα-διαλείπουσα πολλαπλή 
σκλήρυνση που υποβάλλονται σε θεραπεία  με υποδόρια  IFN β-1a 44 μg  ή  22 μg για 12 
μήνες. 
Η μορφή της διπλωματικής εργασίας ακολουθεί την οδηγία Guideline for Good Clinical 
Practice E6 (R1) του  International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) και υποβάλλεται 
στην Αγγλική γλώσσα. 
Στο σημείο αυτό θα ήθελα να ευχαριστήσω τον επιβλέποντα της διπλωματικής μου 
εργασίας, καθηγητή Νευρολογίας κ. Γεώργιο Χατζηγεωργίου, για την ανάθεση του 
θέματος, και τις χρήσιμες υποδείξεις κατά την εκπόνησή της, όπως επίσης και τους 
καθηγητές μου κ.κ. Ηλία Ζιντζαρά και Χρήστο Χατζηχρηστοδούλου, μέλη της τριμελούς 
εξεταστικής επιτροπής, για τις πολύτιμες γνώσεις που μου προσέφεραν κατά τη διάρκεια 
των μεταπτυχιακών μου σπουδών. 
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Brief Title 
Tolerability of Interferon-beta 1-A (Rebif)®  Therapy in patients with Relapsing Remitting 
MS (TIMS). 
This is a prospective, cohort observational study of 250 patients with relapsing-remitting 
MS treated with subcutaneous IFN β-1a 44 μg or 22 μg 3 times weekly for 12 months or 
until early discontinuation.  
 
1. INTRODUCTION/BACKGROUND 
Multiple Sclerosis (MS) is a chronic, demyelinating disease of the central nervous system 
(CNS) characterized by inflammation, demyelination and axonal/neuronal destruction, that 
may lead in the end to severe disability. MS affects currently about 2.5 million patients 
worldwide. Approximately 85% of patients have relapsing-remitting MS (RRMS), 
characterized by recurrent, acute episodes (relapses) of neurological symptoms. After 6-10 
years, 30-40% of patients with RRMS might gradually worsen and progress to secondary 
progressive MS 
Ttreatment with disease-modifying therapy (DMT) can reduce the frequency of disease 
exacerbations and may delay disability progression. Subcutaneous (sc) interferon (IFN) β-
1a (Rebif®; Merck Serono SA, Geneva, Switzerland) has been shown to be effective in 
improving all three key measures of efficacy (relapse rate, disability progression, and 
magnetic resonance imaging measures of disease) in relapsing forms of MS when 
administered at dosages of 44 or 22 μg three times weekly (1-3). Rebif safetely profile is 
generally well established and the drug is used in clinical practice for over 1 0 years with 
over 15 million doses sold since its approval by the U.S. Food and Drug Administration 
(FDA) in 2002 (4). One of the most common and less studied side effects are injection site 
reactions (ISR), and injection site pain that may lead to poor adherence to treatment in 
some patients. 
Several dermatological adverse events have been reported in the literature for MS patients 
treated with IFN β such as severe necrotising cutaneous lesions and severe 
dermatomyositis (5). Most of these events are related to the injection-site reaction and are 
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usually mild-tomoderate local inflammatory reactions. Other events including panniculitis 
(6-7), skin necrosis or ulceration have also been reported. Women seem to be at a greater 
risk of skin reactions due to their higher incidence of autoimmune disease. 
 
1.1 Investigational agent 
Interferon-beta 1-A (Rebif)® 
 
1.2 Trial conduct 
This study will be conducted in compliance with the protocol approved by the Institutional 
Review Board, and according to GCP standards.  No deviation from the protocol will be 
implemented without the prior review and approval of the IRB except where it may be 
necessary to eliminate an immediate hazard to a research subject.  In such case, the 
deviation will be reported to the IRB as soon as possible. 
 
1.3 Population 
Patients with RRMS that take s/c Interferon-beta 1-A (Rebif)®. 
 
2. STUDY OBJECTIVES AND PURPOSE 
 
The purpose of this prospective, observational study in patients with relapsing remitting 
MS, is to assess the tolerability and efficacy of s/c  IFN β-1a; in particular to assess the 
proportion of patients developing injection site reactions (ISR) after a time period of 12 
months. 
 
3. STUDY DESIGN 
 
3.1 Study Endpoints 
 
Primary Study endpoints 
The proportion of patients with moderate to severe injection site reactions based on pain, 
bruising and/or transient (<24 hours) erythema; inflammation alone and with necrosis at 
injection site; even when plastic surgery required for necrosis. 
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Secondary Study endpoints 
 Annual relapse rate  
 Change in EDSS score  
 Time to first relapse  
 Incidence of side effects associated with Rebif therapy 
 
3.2 Type of Study 
 
The study is an observational prospective study. During the screening period demographic 
data, medical history (including history of MS) and details of concommitant 
medications/procedures and medical conditions (safety assessment) were collected. 
Patients underwent neurological examination, a urine pregnancy test (where appropriate) 
and review of inclusion/exclusion criteria. Patients could withdraw from the study at any 
time. 
 
3.3 Treatments of interest 
 
Patients eligible for participation in this study will, as part of their routine medical care, 
receive either  IFN β-1a 44 μg or 22 μg 3 times weekly. The decision on the prescribed 
dose of IFN β-1a, as well as the decision to discontinue treatment, depended on the  
treating physician and reflected the current standard of care in a real-life setting. Patients 
will be followed in the study for 12months. Injection site reactions will be monitored  after  
6 and 12 months of Rebif treatment.Moreover ARR, change in EDSS score, time to first 
relapse and incidence of side effects associated with therapy will be monitored at baseline 
and after 12 months of therapy. 
 
3.4 Study discontinuation 
 
Reasons for the termination of the study include ethical concerns, alterations in accepted 
clinical practice that make the continuation of a clinical trial unwise, and/or reaching a 
positive or negative statistical end point earlier than expected.  Other causes of study 
discontinuation might be commercial such as lack of financial resources. The 
discontinuation of a clinical trial can be decided by either the investigator, the study 
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sponsor, or by mutual agreement.  
 
4. SELECTION AND WITHDRAWAL OF SUBJECTS 
 
4.1 Inclusion criteria 
 
Patients diagnosed with RRMS according to the 2005 McDonald criteria (8) were eligible 
for enrollment in the study if they were aged over 18 years old and did not receive any 
disease-modifying MS therapy before. 
 
4.2 Exclusion criteria 
 
Patients were excluded from the study if they had one of the following criteria:  
 primary progressive or secondary progressive MS 
 previously administered IFN β, glatiramer acetate, any other  immunomodulatory or 
immunosuppressive agents, or any other MS therapy in the  past  
 Initiation of treatment in pregnancy. 
 Subjects with a history of hypersensitivity to interferon-ß, or skin allergies. 
 
4.3 Subject withdrawal 
Subjects have the right to withdraw from the study anytime.  If a subject decides to 
withdraw from the study,  all of the following research activities involving the subject’s 
participation will be discontinued: 
 Interacting or intervening with the subject in order to obtain data about him or her  
 Obtaining additional identifiable private information about the subject by collecting 
or receiving such information from any source  and 
 Obtaining additional identifiable private information about the subject  by 
observing or recording private behavior without interacting or intervening with the subject  
In addition, patients might be withdrawn by the investigator if the investigator feels that 
the patient is not gaining any clinical benefit or because of unacceptable toxicity. Patients 
who are withdrawn or are removed from the study will be required to have an off-study 
clinic visit at the time of discontinuation, a 30-day follow-up safety visit. 
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4.4 Study duration 
The study will be considered  to be completed once the last patient enrolled will have been 
followed for 12 months. 
 
4.5 Procedures for monitoring subject compliance 
Regular contact through phone calls or sms messages with the patients for reminding them 
their treatment dosing schedule. Different contents can be sent to subjects. For the younger, 
the words can be lively and relaxing, and a joke or health tip can be added, while for the 
older a simple and kind message is appropriate . 
Providing rewards or compensation in several forms is also an effective measure including 
oral incentives, advising appropriate holiday, and covering transportation fee.  
Investigators and participants should increase open communication and trust each other.  
Follow-Up Plan 
Follow-up plan should depend on the specific situation of participants such as avoiding 
holidays or any inconvenient day. 
 
5. ASSESSMENT OF EFFICACY 
Efficacy parameters 
The primary endpoint efficacy variable is ISR whereas secondary endpoint efficacy 
variables are ARR, change in EDSS score and time to first relapse. 
 
6. ASSESSMENT OF SAFETY 
 
6.1 Adverse event definitions 
 
Adverse effect. Any untoward medical occurrence in a clinical study of an investigational 
device; regardless of the causal relationship of the problem with the device or, if 
applicable, other study treatment or diagnostic product(s). 
 
Associated with the investigational device or, if applicable, other study treatment or 
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diagnostic product(s).  There is a reasonable possibility that the adverse effect may have 
been caused by the investigational device or, if applicable, the other study treatment or 
diagnostic product(s). 
 
Disability.  A substantial disruption of a person’s ability to conduct normal life functions.  
 
Life-threatening adverse effect.  Any adverse effect that places the subject, in the view of 
the investigator-sponsor, at immediate risk of death from the effect as it occurred (i.e., does 
not include an adverse effect that, had it actually occurred in a more severe form, might 
have caused death). 
 
Serious adverse effect.  An adverse effect is considered “serious” if, in the view of either 
the investigator or the sponsor, it results in any of the following outcomes:  
 death  
 a life-threatening AE 
 inpatient hospitalization or prolongation of existing hospitalization 
 a persistent or significant disability/incapacity 
 a congenital anomaly/birth defect. 
 
Unexpected adverse effect.  Any adverse effect, the frequency, specificity or severity of 
which is not consistent with the risk information described in the clinical study protocol(s) 
or elsewhere in the current IDE application, as amended. 
 
Unanticipated adverse effect: Any adverse effect, the nature, specificity, severity, or 
frequency of which is not consistent with the risk information in the clinical study protocol 
or elsewhere in the current IDE application. 
 
6.2 Eliciting adverse effect information  
 
The subjects of the clinical study will be routinely and regurarly questioned about adverse 
effects at study visits. 
 
6.3 Recording and assessment of adverse effects 
 
All observed adverse effects (serious or non-serious) and abnormal test findings, regardless 
of the group, if applicable, or suspected causal relationship to the investigational device or, 
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if applicable, other study treatment or diagnostic product(s) will be recorded in the 
subjects’ case histories.  For all adverse effects, sufficient information will be pursued 
and/or obtained so as to permit 1) an adequate determination of the outcome of the effect 
(i.e., whether the effect should be classified as a serious adverse effect) and; 2) an 
assessment of the casual relationship between the adverse effect and the investigational 
product or, if applicable, the other study treatment or diagnostic product(s).    
 
Adverse effects or abnormal test findings that are associated with the investigational 
product or, if applicable, other study treatment or diagnostic product(s) will be followed 
until the effect or the abnormal test finding resolves or stabilizes at a level acceptable to the 
investigator-sponsor. 
 
6.4 Reporting of adverse effects to the EMA 
 
The investigator-sponsor will submit a completed  EMA form to the EMA’s Center for 
Devices and Radiological Health for any observed or volunteered adverse effect that is 
determined to be an unanticipated adverse device effect (UADE).  A copy of this completed 
form will be provided to all participating sub-investigators.   
 
The completed Form will be submitted to the EMA as soon as possible and, in no event, 
later than 10 working days after the investigator-sponsor first receives notice of the adverse 
effect. 
 
6.5 Reporting adverse effects to the responsible IRB 
 
For any adverse event determined to be a UADE, the sponsor-investigator will submit the 
completed EMA form and cover letter to the IRB as soon as possible and no later than 10 
working days after the sponsor-investigator first receives notice of the adverse effect. 
Follow-up information to reported adverse effects will be submitted to the IRB as soon as 
the relevant information is available. 
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7. STATISTICAL PLAN 
 
7.1 Sample size determination 
The study is planned to include 125 patients on the Rebif 44mg dosage and 125 patients on 
the 22mg dosage. 
The assumed incidence rates for the parallel cohort were estimated from the observed 
incidence rates by Pelletier et al., 2005 who found that 66.7 % of the patients in the 44mg 
group and 48.5% of the patients in the 22mg group developed ISR.  
20% difference in  ISR between the two groups was considered as clinically important. 
Therefore, the required sample size to detect a statistically significant difference of 20% in 
response at P-value, P=0.05, with a Power 90% is 125 patients in each group. 
 
7.2 Statistical methods 
 
Data for the main variables will be presented using descriptive statistics by using mean, 
median, SD, quartiles, percentages with 95% confidence intervals and extreme values for 
continuous variables, and counts and percentages for categorical variables. The proportion 
of patients with ISR s were not normally distributed between the different patient 
subgroups; therefore, nonparametric tests were used to test the differences between the 
different sc IFN β-1a doses (Mann–WhitneyU-test)  The level of significance will be set at 
p<0.05. 
 
Interim analyses 
A descriptive summary of the data of this study will be performed on a periodic basis (at 
least 3monthly) in addition to the regular periodic safety updates that are required by the 
local health authorities 
 
7.3 Procedure for accounting for any missing, unused and spurious data 
 
Multiple imputation will be used to replace missing values . Multiple imputation is a 
method that makes maximum useof available data and maximises statistical power while 
requiring less strict theoretical assumptions than to a complete case analysis, or single 
imputation of mean values. 
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This  is now one of the methods most commonly used for analysing clinical trials data and 
considered more accurate than the last observation carried forward method (10) 
 
7.4 Procedures for reporting any deviations from the original statistical plan 
 
Any deviations from the original statistical plan will be described and justified in the final 
report. 
 
8. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
 
The investigator and Aristotle University of Thessaloniki will permit trial-related 
monitoring, audits, IRB/IEC review and regulatory inspections by providing direct access  
to source data/documentation. 
 
9. ETHICAL CONSIDERATIONS 
 
9.1 Informed consent procedures 
 
Eligible patients may only be included in the study after providing written (witnessed, 
where required by law or regulation), Institutional Review Board/Independent Ethics 
Committee/Research Ethics Board (IRB/IEC/REB) approved informed consent, or, if 
incapable of doing so, after such consent has been provided by a legally acceptable 
representative of the patient.  
In cases where the patient’s representative gives consent, the patient should be informed 
about the study to the extent possible given his/her understanding. 
If the patient is capable of doing so, he/she should indicate assent by personally signing 
and dating the written informed consent document or a separate assent form. Informed 
consent must be obtained before collecting any data described in this study protocol. The 
process of obtaining informed consent should be documented in the patient source 
documents. 
 
9.2 Responsibilities of the investigator and IRB/IEC 
 
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted IRB/IEC or equivalent board reviewing specifically non-interventional 
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study protocol, before the start of the study. Prior to study start, the treating physician is 
required to sign a protocol signature page confirming his/her agreement to conduct the 
study in accordance with these documents and all of the instructions and procedures that 
are found in this protocol. 
 
9.3 Early termination of the study 
 
The study can be terminated at any time for any reason after  agreement with health 
authorities. The treating physician might be informed of the procedures that need to be 
followed in order to make sure that adequate consideration is given to the protection of the 
patient’s interests. The participating physician will be responsible for informing the 
IRB/IEC of the early termination of the study. 
 
10. DATA HANDLING AND RECORD KEEPING 
A Case Report Form (CRF) will be completed for each subject that is enrolled into the 
clinical study. Trained site staff will enter protocol defined data in the CRF. The 
investigator-sponsor will review, approve and sign/date each completed CRF; the 
investigator-sponsor’s signature serving as attestation of the investigator-sponsor’s 
responsibility for ensuring that all clinical data entered on the CRF are complete and 
accurate. 
In any case, the physician must maintain source documents for each patient in the 
study,consisting of case and visit notes (hospital or clinic medical records) containing 
demographic and medical information, and the results of any tests performed. 
All information entered in the CRF must be traceable to these source documents in the 
patient’s file. The physician must also keep the original informed consent form signed by 
the patient (a signed copy is given to the patient). 
The investigator must arrange for the retention of the subject identification codes for a 
sufficient period of time to permit any medical follow-up which may be warranted. 
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11. LIMITATIONS 
This is an observational, non-randomized study, therefore different biases may occur. 
Systematic differences between the 2 patient cohorts may exist, influenced by clinical 
decisions of the treating physicians that will assign patients to different drug dosage based 
mostly on disease severity but also disease duration, presence of comorbidities, and other 
factors. These differences can potentially introduce channeling bias and confound the 
association between treatment and the risk of the safety outcome. 
 
12. PUBLICATION POLICY 
 
The protocol and the key results will be posted in a publicly accessible database such as 
clinicaltrials.gov. Moreoever, at least upon study completion and finalization of the study 
report the results of this study will be either submitted for publication in a peer-reviewed 
journal or presented in a conference and/or posted in a publicly accessible database of 
study results. 
 
13. FINANCING AND INSURANCE 
 
The clinical study is funded by the Aristotle University of Thessaloniki. The insurance of 
the  subjects that participate will be covered by their health insurance. Any extra costs 
needed will be covered by the Aristotle University of Thessaloniki. 
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15.  SUPPLEMENT 
 
Flow Chart 
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